Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
This article was originally published in PharmAsia News
Just days after the publication of promising data concerning its antibiotic drug candidate fidaxomicin, Optimer Pharmaceuticals Inc. has licensed the compound to Astellas Pharma Europe Ltd. to treat Clostridium difficile infections in Europe and additional territories
You may also be interested in...
Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area
Theravance expects an FDA advisory committee review for Vibativ in hospital acquired pneumonia; product partnered with Astellas is approved for complicated skin infections.
Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.